AMDL receives Israeli patent for animal model for the evaluation of vaccines AMDL.

This is a variation of the traditional concept of gene therapy, which seeks to replace damaged or unusual genes with healthy ones. Changing defective genes in tumor cells has confirmed impractical because of the true number of genes involved. CIT has undergone effective Phase I medical trials in pores and skin and brain cancer sufferers and was shown to be 100 % effective in a humanized mouse model at the University of Alberta, Canada. Publications that have reported upon this therapy include ‘Human being Gene Therapy’ and ‘Neurosurgery.’ Currently AMDL holds patents for the ‘humanized mouse’ in the U.S., Australia and Singapore.‘Acacia is quickly becoming the leader in technology licensing and we continue to grow our bottom of future revenues with the addition of new patent portfolios,’ concluded Mr. Ryan.

Allergan acquires Serica Technologies Morningside Technology Ventures, Prism VentureWorks, and Ivy Capital Partners are very happy to announce the acquisition of their portfolio company, Serica Technology, Inc. By Allergan, Inc. Serica is a growth-stage medical device business focused on the development of biodegradable silk-centered scaffolds for make use of in tissue regeneration in several therapeutic areas. Following a acquisition, Serica became a possessed subsidiary of Allergan wholly.